Tanabe Seiyaku Explores Possible Merger with Mitsubishi Pharma - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Tanabe Seiyaku Explores Possible Merger with Mitsubishi Pharma

ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Tokyo (Jan. 18)Tanabe Seiyaku Co. Ltd. (www.tanabe.co.jp/english) confirmed it has had discussions with Mitsubishi Pharma Corporation (www.m-pharma.co.jp) over a possible merger between the two companies, but that no definite decision has been made for such a deal.

“Tanabe has been discussing with Mitsubishi Pharma on a potential merger between the two companies for the purpose of expansion of business scale and reinforcement of management infrastructure to respond to the competitive environment surrounding the pharmaceutical market and survive intensifying global competition,” said Tanabe Seiyaku in a prepared statement. “However, no concrete decision has been made in this regard.”

A potential merger between Tanabe Seiyaku and Mitsubishi Pharma follows recent consolidation in the Japanese pharmaceutical industry. In 2005, Sanyko and Daiichi Pharmaceuticals merged to form Daiichi Sanyko Co. Ltd. (Tokyo, www.daiichipharm.co.jp/english), and Fujisawa Pharmaceutical Co., Ltd. and Yamanouchi Pharmaceutical Co., Ltd. merged to form Astellas Pharma Inc. (Tokyo, www.astellas.com).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here